- Home
- SEAT vs TRVI Comparison
SEAT vs TRVI Comparison
Compare SEAT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- TRVI
- Stock Information
- Founded
- SEAT 2001
- TRVI 2011
- Country
- SEAT United States
- TRVI United States
- Employees
- SEAT N/A
- TRVI N/A
- Industry
- SEAT Industrial Machinery/Components
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SEAT Industrials
- TRVI Health Care
- Exchange
- SEAT Nasdaq
- TRVI Nasdaq
- Market Cap
- SEAT 366.2M
- TRVI 383.4M
- IPO Year
- SEAT N/A
- TRVI 2019
- Fundamental
- Price
- SEAT $1.79
- TRVI $6.61
- Analyst Decision
- SEAT Buy
- TRVI Strong Buy
- Analyst Count
- SEAT 11
- TRVI 8
- Target Price
- SEAT $4.49
- TRVI $17.56
- AVG Volume (30 Days)
- SEAT 2.5M
- TRVI 1.3M
- Earning Date
- SEAT 05-06-2025
- TRVI 05-08-2025
- Dividend Yield
- SEAT N/A
- TRVI N/A
- EPS Growth
- SEAT N/A
- TRVI N/A
- EPS
- SEAT N/A
- TRVI N/A
- Revenue
- SEAT $748,757,000.00
- TRVI N/A
- Revenue This Year
- SEAT N/A
- TRVI N/A
- Revenue Next Year
- SEAT $5.90
- TRVI N/A
- P/E Ratio
- SEAT N/A
- TRVI N/A
- Revenue Growth
- SEAT 0.82
- TRVI N/A
- 52 Week Low
- SEAT $1.66
- TRVI $2.30
- 52 Week High
- SEAT $5.90
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- SEAT 30.99
- TRVI 56.38
- Support Level
- SEAT $2.65
- TRVI $6.37
- Resistance Level
- SEAT $1.90
- TRVI $7.24
- Average True Range (ATR)
- SEAT 0.17
- TRVI 0.42
- MACD
- SEAT -0.08
- TRVI -0.01
- Stochastic Oscillator
- SEAT 9.63
- TRVI 50.38
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.